Freedom of information requests

Breast cancer

Questions

1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:

a) Abemaciclib monotherapy 

b) aromatase inhibitor monotherapy 

c) Tamoxifen monotherapy 

d) Abemaciclib + Tamoxifen 

 

2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:

a) Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)

b)Taxane and/or Anthracycline (monotherapy or in combination)

c)Any other active systemic anti-cancer therapy

 

3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

a)Anthracycline (e.g. doxorubicin or epirubicin) as a single agent

b)Atezolizumab +Nab-paclitaxel/Paclitaxel

c)Pembrolizumab

d)Sacituzumab Govitecan

e)Parp Inhibitors (Olaparib/Talazoparib)

f)Eribulin as a single agent or in combination

g)Capecitabine as a single agent

h)Platinum (e.g. carboplatin or cisplatin) as a single agent

i)Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent

j)Taxane and/or Anthracycline in combination

k)Any other active systemic anti-cancer therapy

 

Response

1. 

Drug	Number of patients
Abemaciclib monotherapy	0
Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)	53
Tamoxifen monotherapy	10
Abemaciclib + Tamoxifen	0

2. 

Drug	Number of patients
Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)	53
Taxane and/or Anthracycline (monotherapy or in combination)	0
Any other active systemic anti-cancer therapy	0

3. 

Drug	Number of patients
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	85
Atezolizumab +Nab-paclitaxel/Paclitaxel	0
Pembrolizumab	0
Sacituzumab Govitecan	0
Parp Inhibitors (Olaparib/Talazoparib)	0
Eribulin as a single agent or in combination	6
Capecitabine as a single agent	0
Platinum (e.g. carboplatin or cisplatin) as a single agent	0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	14
Taxane and/or Anthracycline in combination	0
Any other active systemic anti-cancer therapy	0